Cathy Eng, MD, FACP, FASCO

Cathy Eng, MD, FACP, FASCO

Cathy Eng, MD, FACP, FASCO

Cathy Eng, MD, FACP, FASCO, Professor of Medicine, Hematology and Oncology, is the David H. Johnson Endowed Chair of Surgical and Medical Oncology, Co-Director of GI Oncology and the Co-Leader of the Gastrointestinal Cancer Research Program, Director of the new Young Adults Cancers Program, and the Chair, Developmental Research Program for the GI SPORE, at the Vanderbilt-Ingram Cancer Center. She served as the Ambassador for the American Cancer Society ResearcHERS campaign in Nashville (2020-2022). She is currently the Director for Strategic Relations for Vanderbilt-Ingram Cancer Center.   She has served on the Scientific Review Committee and remains on the Clinical Trials Shared Resource Oversite Committee.  She is a highly sought mentor and served on the Vanderbilt-Ingram Mentorship Council and is currently a mentor on the T-32 grant and serves as a Professional Development Mentor.  She continues to assume leadership positions devoted to development of phase I-III clinical trials using novel therapeutics for biomarker discovery and enhanced drug utilization in colorectal, appendiceal and anal cancer patients.

Nationally, Dr. Eng has also been highly active serving on ASCO, ECOG, and SWOG.  She has served on multiple committees for ASCO including the Career Development Committee, Education Committee for Colorectal Cancer; ASCO Scientific Program Committee Track Leader for the Gastrointestinal Cancer-Colorectal/Liver Track and served on the Steering Committee 2012-2015.  She is the former Chairman of the Scientific Program Committee of the ASCO Gastrointestinal Cancer Symposium from 2012-2013 and Chairman, Steering Committee, GI Cancers Symposium 2016.  She was chosen for the ASCO Leadership Development Program and served on the ASCO Government Relations Committee; worked with the ASCO Cancer Prevention Committee on the consensus statement regarding HPV vaccination; served on the ASCO Nausea and Vomiting Guidelines Committee, ASCO Taxonomy Task Force, ASCO Social Media Committee, and is currently on the ASCO Colorectal Guidelines Committee, ASCO Scientific Program Committee (Colorectal Cancer Track) and the ASCO Communications Committee. She was the co-chair of the SWOG Rectal/Anal Cancer Subcommittee and was the Vice-Chair for the SWOG GI Committee. She was the Chairman of the NCI Rectal/Anal Task Force (two terms), served on the NCI GI Steering Committee, and is now the co-Chair of the NCI GI Steering Committee.

She has published in many peer-reviewed journals including Journal of Clinical Oncology, Lancet Oncology, Nature Review, JNCI, Annals of Oncology, Cancer, and Annals of Surgical Oncology.  She has previously received an NCI grant “Administrative Supplements to the institutional CCSG grant to Support Biomarker Studies Associated with NCI-supported Clinical Trials of Immunotherapy”.  She was a co-PI for the MD Anderson Moonshot for HPV-Associated Malignancies (Section Lead for the Rare Cancers subsection) and continues to serve as a grant reviewer on the MD Anderson Colorectal Cancer Moonshot Grant and the Sabine award. She has served as a consultant to the FDA and AHRQ, Cancer Research UK: Training & Career Development Board – Clinician Scientist Fellowship, the Italian Association for Cancer Research, the Dutch Digestive Foundation, the Stand Up to Cancer (SU2C) – Farrah Fawcett Foundation Joint Scientific Advisory Committee (JSAC) and the SWOG Impact Award.

Articles by Cathy Eng, MD, FACP, FASCO

Cathy Eng, MD, FACP, FASCOColorectal Cancer | March 21, 2025
Dr. Eng discusses the rising global incidence of early-onset CRC, as highlighted in a recent Lancet Oncology publication.
View More
Cathy Eng, MD, FACP, FASCOAdvancements in Oncology | March 19, 2025
Dr. Eng opines on how the ESOPEC study will alter the treatment paradigm for patients with esophageal/GEJ adenocarcinoma.
Cathy Eng, MD, FACP, FASCOColorectal Cancer | March 19, 2025
Dr. Eng comments on how she approaches treatment considerations and management for her younger patients with colon cancer.
Cathy Eng, MD, FACP, FASCOColorectal Cancer | March 19, 2025
Dr. Eng explains how she makes sense of the stage 4 third-line therapy options to administer to her colon cancer patients.
Cathy Eng, MD, FACP, FASCOColorectal Cancer | March 19, 2025
Dr. Eng shares what the COMMIT study suggest about colon cancer and this study's applicability outside of liver metastasis.
Cathy Eng, MD, FACP, FASCOColorectal Cancer | March 19, 2025
Dr. Eng provides her thoughts on ctDNA upfront, sequential, and combined with NGS testing for patients with colon cancer.
Cathy Eng, MD, FACP, FASCOColorectal Cancer | March 19, 2025
Dr. Eng discusses how fruquintinib differs from other VEGFR inhibitors.
Michael Lidsky, MDColorectal Cancer | March 19, 2025
Drs. Lidsky and Eng discuss PUMP, a phase 3 trial of HAI for treating patients with CRC and unresectable liver metastases.
Cathy Eng, MD, FACP, FASCOColorectal Cancer | September 13, 2023
Dr. Eng discusses the phase 3 FRESCO-2 study and how fruquintinib fits in with current treatments for advanced CRC.